Tom 9, Nr 6 (2015)
Wybrane problemy kliniczne
Opublikowany online: 2016-01-21
Wyświetlenia strony
755
Wyświetlenia/pobrania artykułu
3595
Zastosowanie akarbozy w różnych stanach zaburzeń metabolizmu glukozy
Forum Medycyny Rodzinnej 2015;9(6):443-446.
Streszczenie
Inhibitory alfa-glukozydazy poprawiają zależność czasową między wzrostem w osoczu insuliny oraz stężenia glukozy po posiłku. W związku z tym środki te mogą być stosowane w leczeniu pacjentów z cukrzycą typu 2 w monoterapii lub w połączeniu z innymi lekami. Inhibitory alfa-glukozydazy mogą również okazać się przydatne jako uzupełnienie leczenia insuliną u pacjentów z cukrzycą typu 1 czy w prewencji innych form zaburzeń metabolizmu glukozy. Akarboza jest uważana za preparat bezpieczny i efektywny.
Słowa kluczowe: cukrzycainsulinoopornośćinhibitory alfa-glukozydazy
Referencje
- Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2014. Stanowisko PTD. Clinical Diabetology. 2015; 4(supl. A).
- Drzewoski J. „Staruszka” metformina potwierdza swoje ogromne znaczenie terapeutyczne. Diabetologia po Dyplomie. 2012; 9: 27–29.
- Otto-Buczkowska E. Cukrzyca typu 1 — co nowego w prewencji i programach terapii? Med Matabol. 2013; 17: 84–90.
- Otto-Buczkowska E. Metformina — blaski i cienie jej stosowania u młodych pacjentów. Dylematy refundacyjne Med Rodz. 2013; 16: 154–157.
- Holman RR, Bethel MA, Chan JCN, et al. ACE Study Group. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. Am Heart J. 2014; 168(1): 23–29.
- Joshi SR, Ramachandran A, Chadha M, et al. Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes. Expert Opin Pharmacother. 2014; 15(11): 1611–1620.
- Standl E, Theodorakis MJ, Erbach M, et al. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol. 2014; 13: 81.
- Punthakee Z, Miller ME, Simmons DL, et al. ACCORD Group of Investigators. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. Diabetologia. 2014; 57(10): 2030–2037.
- Su B, Liu H, Li J, et al. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. J Diabetes. 2014; 7(5): 729–739.
- Weng J, Soegondo S, Schnell O, et al. Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database. Diabetes Metab Res Rev. 2015; 31(2): 155–167.
- Zhang W, Kim D, Philip E, et al. Gluco VIP study. A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study. Clin Drug Investig. 2013; 33(4): 263–274.
- Chen PH, Tsai YT, Wang JS, et al. Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose. Diabetol Metab Syndr. 2014; 6: 68.
- Gabbay Md. [Adjunctive therapies to glycaemic control of type 1 diabetes mellitus]. Arq Bras Endocrinol Metabol. 2008; 52(2): 279–287.
- Scheen AJ. [Limited add-on value of oral glucose-lowering agents in type 1 diabetes]. Rev Med Liege. 2013; 68(1): 16–21.
- Sels JP, Verdonk HE, Wolffenbuttel BH. Effects of acarbose (Glucobay) in persons with type 1 diabetes: a multicentre study. Diabetes Res Clin Pract. 1998; 41(2): 139–145.
- Ma Yr, Xu Yc, Ge Jp. [Improvement in blood glucose fluctuations of insulin-treated type 1 diabetic patients with additional use of acarbose and assessed by continuous blood glucose monitoring program]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012; 33(8): 854–856.
- Neuser D, Benson A, Brückner A, et al. Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clin Drug Investig. 2005; 25(9): 579–587.
- Juntti-Berggren L, Pigon J, Hellström P, et al. Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes. Diabetes Nutr Metab. 2000; 13(1): 7–12.
- Rabasa-Lhoret R, Burelle Y, Ducros F, et al. Use of an alpha-glucosidase inhibitor to maintain glucose homoeostasis during postprandial exercise in intensively treated Type 1 diabetic subjects. Diabet Med. 2001; 18(9): 739–744.
- Raptis SA, Dimitriadis GD. Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers. Exp Clin Endocrinol Diabetes. 2001; 109 Suppl 2: S265–S287.
- Riccardi G, Giacco R, Parillo M, et al. Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med. 1999; 16(3): 228–232.
- Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. Diabetes Care. 1997; 20(3): 248–253.
- Dash S, Crisp S, Hartnell S, et al. Successful use of acarbose to manage post-prandial glycaemia in two patients with type 1 diabetes on continuous subcutaneous insulin infusion. Diabetes Res Clin Pract. 2012; 95(3): e49–e51.
- Scheen AJ. [Limited add-on value of oral glucose-lowering agents in type 1 diabetes]. Rev Med Liege. 2013; 68(1): 16–21.
- Maule S, Tredici M, Dematteis A, et al. Postprandial hypotension treated with acarbose in a patient with type 1 diabetes mellitus. Clin Auton Res. 2004; 14(6): 405–407.
- Munakata Y, Yamada T, Takahashi K, et al. A case of slowly progressive type 1 diabetes with insulin independence maintained for 10 years with α-glucosidase inhibitor monotherapy. Intern Med. 2012; 51(24): 3391–3394.
- Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trial Research Group, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4): 486–494.
- Hanefeld M, Schaper F, Koehler C. Effect of acarbose on vascular disease in patients with abnormal glucose tolerance. Cardiovasc Drugs Ther. 2008; 22(3): 225–231.
- Chiasson JL. ACARBOSE FOR THE PREVENTION OF DIABETES, HYPERTENSION, AND CARDIOVASCULAR DISEASE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE: THE STUDY TO PREVENT NON-INSULIN-DEPENDENT DIABETES MELLITUS (STOP-NIDDM) TRIAL. Endocrine Practice. 2006; 12(Supplement 1): 25–30.
- DeFronzo RA, Abdul-Ghani MA. Preservation of β-cell function: the key to diabetes prevention. J Clin Endocrinol Metab. 2011; 96(8): 2354–2366.
- Smith-Marsh D. Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance. Drugs Today (Barc). 2013; 49(8): 499–507.
- Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev. 2006(4): CD005061.
- Merlotti C, Morabito A, Pontiroli AE. Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies. Diabetes Obes Metab. 2014; 16(8): 719–727.
- DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care. 2011; 34 Suppl 2: S202–S209.
- Hanefeld M, Karasik A, Koehler C, et al. Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial. Diab Vasc Dis Res. 2009; 6(1): 32–37.
- Yamagishi Si, Matsui T, Ueda S, et al. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. Curr Drug Metab. 2009; 10(2): 159–163.
- Derosa G, Maffioli P, D'Angelo A, et al. RETRACTED: Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study. J Diabetes Complications. 2011; 25(4): 258–266.
